Addressing unmet medical needs in disorders of the complement and coagulation systems
Harnessing the catalytic power of proteases
Protease engineering platform – Late-stage asset in Phase 3, robust complement portfolio, clinical-stage hemophilia assets, and differentiated protease medicines
Learn more about our Pipeline
SQ Marzeptacog alfa (activated) MarzAA (FVIIa)
Phase 3
CB 2782-PEG
IVT Anti-C3 Dry AMD
CB 4332 SQ Enhanced CFI
SQ Systemic Complement Degraders
SQ MarzAA (FVIIa)
SQ Dalcinonacog alfa – DalcA (FIX)
Factor IX Gene Therapy
Factor Xa
Learn more about the medicines we are developing
See our pipeline
Share our passion about treating disease
See our publications
Learn more about the Catalyst team and mission/culture
Meet the team